579492-81-2

Bax inhibitor peptide V5 is an inhibitor of Bax. It decreases levels of the pro-apoptotic proteins Bax, Bad, and NF-ĸB p65 and increases levels of the anti-apoptotic proteins X-linked inhibitor of apoptosis (XIAP) and Bcl-2 in isolated mouse pancreatic islets when used at a concentration of 100 μM. It inhibits apoptosis induced by etoposide (Item No. 12092) in Hep3B human hepatoma cells when used at a concentration of 200 μM. Bax inhibitor peptide V5 (5 mg/ml, i.c.v.) decreases infarct volume and reduces ipsilateral paw preference in the cylinder rearing test, indicating an improvement in sensorimotor function, in a neonatal mouse model of hypoxic-ischemia brain injury induced by carotid artery ligation. Bax inhibitor peptide V5, when used at a concentration of 100 μM in syngeneic pancreatic islet cells prior to transplantation, inhibits increases in blood glucose levels in an intraperitoneal glucose tolerance test and increases survival in a mouse model of diabetes induced by streptozotocin (STZ; Item No. 13104).

Bax inhibitor peptide V5 (BIP-V5) is a Bax-mediated apoptosis inhibitor, used for cancer treatment.

BAX Inhibiting Peptide V5 protects Bax against conformational changes and it also prevents mitochondrial translocation. In vitro analysis prove that peptide V5 prevents apoptosis, mediated by a number of agents including staurosporine, ultraviolet and anti-cancer drug.

Bax

[1]. sawada m, hayes p, matsuyama s. cytoprotective membrane-permeable peptides designed from the bax-binding domain of ku70. nat cell biol, 2003, 5(4): 352-357.
[2]. rivas-carrillo jd, soto-gutierrez a, navarro-alvarez n, et al. cell-permeable pentapeptide v5 inhibits apoptosis and enhances insulin secretion, allowing experimental single-donor islet transplantation in mice. diabetes, 2007, 56(5): 1259-1267.